In the present study, we examined plasma glucagon concentrations and glucagon suppression after oral glucose intake in a group of individuals at high risk for type 2 diabetes (prediabetes) undergoing atorvastatin therapy. This evidence concerns the gene GCG and type 2 diabetes mellitus.